These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11038435)

  • 1. Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects.
    Modi NB; Wang B; Hu WT; Gupta SK
    Biopharm Drug Dispos; 2000 Jan; 21(1):23-31. PubMed ID: 11038435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS (methylphenidate HCl) formulation.
    Modi NB; Lindemulder B; Gupta SK
    J Clin Pharmacol; 2000 Apr; 40(4):379-88. PubMed ID: 10761165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.
    Teo SK; Scheffler MR; Wu A; Stirling DI; Thomas SD; Stypinski D; Khetani VD
    J Clin Pharmacol; 2004 Feb; 44(2):173-8. PubMed ID: 14747426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fed and Fasted Administration of a Novel Extended-Release Methylphenidate Orally Disintegrating Tablet Formulation for the Treatment of ADHD.
    Weisler RH; Stark JG; Sikes C
    Clin Pharmacol Drug Dev; 2018 Feb; 7(2):160-167. PubMed ID: 28544344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative bioavailability of single-dose methylphenidate from a multilayer-release bead formulation and an osmotic system: a two-way crossover study in healthy young adults.
    Reiz JL; Donnelly GA; Michalko K
    Clin Ther; 2008 Jan; 30(1):59-69. PubMed ID: 18343243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-proportional and stereospecific pharmacokinetics of methylphenidate delivered using an osmotic, controlled-release oral delivery system.
    Modi NB; Wang B; Noveck RJ; Gupta SK
    J Clin Pharmacol; 2000 Oct; 40(10):1141-9. PubMed ID: 11028253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adults.
    Markowitz JS; Straughn AB; Patrick KS; DeVane CL; Pestreich L; Lee J; Wang Y; Muniz R
    Clin Pharmacokinet; 2003; 42(4):393-401. PubMed ID: 12648029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce.
    Lee L; Kepple J; Wang Y; Freestone S; Bakhtiar R; Wang Y; Hossain M
    Biopharm Drug Dispos; 2003 Sep; 24(6):233-43. PubMed ID: 12973820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of food on early drug exposure from extended-release stimulants: results from the Concerta, Adderall XR Food Evaluation (CAFE) Study.
    Auiler JF; Liu K; Lynch JM; Gelotte CK
    Curr Med Res Opin; 2002; 18(5):311-6. PubMed ID: 12240794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-proportional pharmacokinetics of a methylphenidate extended-release capsule.
    Rochdi M; González MA; Dirksen SJ
    Int J Clin Pharmacol Ther; 2004 May; 42(5):285-92. PubMed ID: 15176652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women.
    Teo SK; Scheffler MR; Kook KA; Tracewell WG; Colburn WA; Stirling DI; Thomas SD
    Biopharm Drug Dispos; 2000 Jan; 21(1):33-40. PubMed ID: 11038436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methylphenidate bioavailability from two extended-release formulations.
    González MA; Pentikis HS; Anderl N; Benedict MF; DeCory HH; Dirksen SJ; Hatch SJ
    Int J Clin Pharmacol Ther; 2002 Apr; 40(4):175-84. PubMed ID: 11996212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pharmacokinetic study of two modified-release methylphenidate formulations under different food conditions in healthy volunteers.
    Haessler F; Tracik F; Dietrich H; Stammer H; Klatt J
    Int J Clin Pharmacol Ther; 2008 Sep; 46(9):466-76. PubMed ID: 18793577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans.
    Parasrampuria DA; Schoedel KA; Schuller R; Gu J; Ciccone P; Silber SA; Sellers EM
    J Clin Pharmacol; 2007 Dec; 47(12):1476-88. PubMed ID: 17962423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized Controlled Crossover Trials of the Pharmacokinetics of PRC-063, a Novel Multilayer Extended-Release Formulation of Methylphenidate, in Healthy Adults.
    Katzman MA; Mattingly G; Klassen LJ; Cataldo MJ; Donnelly GAE
    J Clin Psychopharmacol; 2020; 40(6):579-587. PubMed ID: 33009228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule.
    Pentikis HS; Simmons RD; Benedict MF; Hatch SJ
    J Am Acad Child Adolesc Psychiatry; 2002 Apr; 41(4):443-9. PubMed ID: 11931601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria.
    Shram MJ; Quinn AM; Chen N; Faulknor J; Luong D; Sellers EM; Endrenyi L
    Clin Ther; 2012 May; 34(5):1170-81. PubMed ID: 22512898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-dose pharmacokinetics of NWP06, an extended-release methylphenidate suspension, in children and adolescents with ADHD.
    Childress AC; Sallee FR; Berry SA
    Postgrad Med; 2011 Sep; 123(5):80-8. PubMed ID: 21904089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The single-dose pharmacokinetics of NWP06, a novel extended-release methylphenidate oral suspension.
    Childress AC; Berry SA
    Postgrad Med; 2010 Sep; 122(5):35-41. PubMed ID: 20861586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.